切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2024, Vol. 18 ›› Issue (05) : 257 -263. doi: 10.3877/cma.j.issn.1674-0807.2024.05.001

专家论坛

多基因检测在早期乳腺癌辅助治疗中的应用价值
葛睿1,(), 陈飞2, 李杰3, 李娟娟4, 陈涵5   
  1. 1.200040 上海,复旦大学附属华东医院普外科
    2.200060 上海,同济大学附属普陀人民医院普外科
    3.510623 广州,广州医科大学附属妇女儿童医疗中心甲状腺乳腺疾病诊疗中心
    4.430060 武汉,武汉大学人民医院乳腺甲状腺外科
    5.200052 上海,解放军海军第905医院普外科
  • 收稿日期:2024-09-24 出版日期:2024-10-01
  • 通信作者: 葛睿
  • 基金资助:
    北京科创医学发展基金(KC2023-JX-0082-09)同济大学附属普陀区人民医院课题(2023rmky06)

Application of multi-gene panel testing in adjuvant therapy for early breast cancer

Rui Ge1,(), Fei Chen2, Jie Li3, Juanjuan Li4, Han Chen5   

  1. 1.Department of General Surgery, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, China
    2.Department of General Surgery, Putuo People’s Hospital Affiliated to Tongji University, Shanghai 200060, China
    3.Department of Breast and Thyroid Surgery,Guangzhou Women and Children’s Medical Center, Guangzhou 510623, China
    4.Breast and Thyroid Center,People’s Hospital of Wuhan University, Wuhan 430060, China
    5.Department of General Surgery,PLA Navy 905 Hospital, Shanghai 200052, China
  • Received:2024-09-24 Published:2024-10-01
  • Corresponding author: Rui Ge
引用本文:

葛睿, 陈飞, 李杰, 李娟娟, 陈涵. 多基因检测在早期乳腺癌辅助治疗中的应用价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 257-263.

Rui Ge, Fei Chen, Jie Li, Juanjuan Li, Han Chen. Application of multi-gene panel testing in adjuvant therapy for early breast cancer[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(05): 257-263.

多基因检测为早期乳腺癌辅助治疗提供了新的策略和方法。 随着基因组学技术的不断发展和应用,多基因检测在早期乳腺癌的预后评估、疗效预测和治疗决策中发挥着越来越重要的作用。目前,多基因检测已在激素受体阳性、HER-2 阴性乳腺癌的化疗决策、内分泌延长治疗和辅助放射治疗决策中显示出显著价值,同时在三阴性乳腺癌的新辅助治疗中也展现出应用潜力。 在HER-2 阳性乳腺癌中的应用也有一些探索,但仍需进一步确认其临床价值。 本文就目前临床应用的多基因检测工具在早期乳腺癌个体化辅助治疗中的价值进行综述,为临床实践提供参考。

Multi-gene panel testing has provided new strategies and approaches for adjuvant therapy in early breast cancer. With continuous development and application of genomic technologies, multi-gene panel testing plays an increasingly important role in prognosis evaluation, efficacy prediction, and treatment decisionmaking in early breast cancer. Currently, multi-gene panel testing has shown a significant value in chemotherapy decision-making, extended endocrine therapy, and adjuvant radiotherapy decision-making for hormonal receptor positive and HER-2 negative (HR+/HER-2-) breast cancer, and potentials in neoadjuvant therapy for triple negative breast cancer. Some explorative studies are conducted in HER-2-positive breast cancer, but its value still needs further confirmation. This article reviewed the application of multi-gene panel testing tools clinically used in individualized adjuvant therapy for early breast cancer, providing a reference for clinical practice.

表1 目前用于乳腺癌患者的多基因检测工具
[1]
Siegel RL,Giaquinto AN, Jemal A. Cancer statistics, 2024 [J]. CA Cancer J Clin, 2024, 74(1): 12-49.
[2]
Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies--improving the management of early breast cancer: St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [J]. Ann Oncol, 2015, 26(8): 1533-1546.
[3]
Cobain EF, Hayes DF. Indications for prognostic gene expression profiling in early breast cancer [J]. Curr Treat Options Oncol, 2015,16(5):23.
[4]
Huang J, Luo Q, Tan Q, et al. Evaluation of the surgical fat-filling procedure in the treatment of refractory cough after systematic mediastinal lymphadenectomy in patients with right lung cancer [J]. J Surg Res,2014,187(2):490-495.
[5]
Ji JH, Ahn SG, Yoo Y, et al. Prediction of a multi-gene assay(Oncotype DX and Mammaprint) recurrence risk group using machine learning in estrogen receptor-positive, HER2-negative breast cancer-the BRAIN study [J]. Cancers (Basel),2024,16(4):774.
[6]
Andre F, Ismaila N, Henry NL, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline updateintegration of results from TAILORx [J]. J Clin Oncol, 2019,37(22): 1956-1964.
[7]
Venetis K, Pescia C, Cursano G, et al. The evolving role of genomic testing in early breast cancer: Implications for diagnosis, prognosis,and therapy [J]. Int J Mol Sci, 2024, 25(11):5717.
[8]
Davey MG, Cleere EF, O'donnell JP, et al. Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network metaanalysis [J]. Breast Cancer Res Treat, 2022, 193(3): 535-544.
[9]
Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer [J]. N Engl J Med, 2015,373(21): 2005-2014.
[10]
Zeng C, Zhang J. A narrative review of five multigenetic assays in breast cancer [J]. Transl Cancer Res,2022,11(4):897-907.
[11]
中国抗癌协会国际医疗与交流分会, 中国医师协会肿瘤医师分会乳腺癌学组. 激素受体阳性人表皮生长因子受体2 阴性早期乳腺癌术后辅助治疗多基因检测应用专家共识(2023 版) [J]. 中华肿瘤杂志, 2023, 45(10): 863-870.
[12]
杨红健, 俞星飞, 陈俊青,等. 浙江省早期乳腺癌辅助治疗多基因检测应用专家共识(2020 版) [J/CD]. 中华乳腺病杂志(电子版),2021,15(5):263-274.
[13]
Lindström LS, Yau C, Czene K, et al. Intratumor heterogeneity of the estrogen receptor and the long-term risk of fatal breast cancer [J]. J Natl Cancer Inst, 2018, 110(7): 726-733.
[14]
Hochheiser L, Hornberger J,Turner M,et al. Multi-gene assays:effect on chemotherapy use, toxicity and cost in estrogen receptor-positive early stage breast cancer [J]. J Comp Eff Res,2019,8(5):289-304.
[15]
Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer [J]. N Engl J Med, 2018, 379(2): 111-121.
[16]
Paik S. Expression of the 21 genes in the recurrence score assay and tamoxifen clinical benefit in the NSABP study B-14 of node-negative,estrogen receptor-positive breast cancer [J]. ASCO,2005,69(1):17-21.
[17]
Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer [J]. J Clin Oncol, 2006, 24(23): 3726-3734.
[18]
Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer [J]. N Engl J Med,2019, 380(25): 2395-2405.
[19]
Sparano JA, Gray RJ, Makower DF, et al. Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial [J]. JAMA Oncol, 2020,6(3): 367-374.
[20]
Woodward WA, Barlow WE, Jagsi R, et al. Association between 21-gene assay recurrence score and locoregional recurrence rates in patients with node-positive breast cancer [J]. JAMA Oncol,2020,6(4):505-511.
[21]
Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer [J]. N Engl J Med, 2021, 385(25): 2336-2347.
[22]
O'shaughnessy J, Graham CL, Whitworth P, et al. Association of MammaPrint index and 3-year outcome of patients with HR +HER2-early-stage breast cancer treated with chemotherapy with or without anthracycline [J]. J Clin Oncol, 2024, 42(16-suppl): 511.
[23]
Huang TT, Lei L, Chen CA, et al. A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients [J]. Sci Rep, 2020, 10(1): 4861.
[24]
Casasanta N, Patel R, Raymond S, et al. Correlating predicted adjuvant therapy benefit and risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX recurrence score (RS)[J]. Clin Breast Cancer, 2024, 24(7): 585-596.
[25]
Sestak I, Buus R, Cuzick J, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial [J]. JAMA Oncol,2018, 4(4): 545-553.
[26]
Bartlett JM, Bayani J, Marshall A, et al. Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others [J]. J Natl Cancer Inst, 2016, 108(9): djw050.
[27]
Woolpert KM, Ahern TP, Lash TL, et al. Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis [J]. Breast Cancer Res Treat, 2024,203(3): 407-417.
[28]
Bartlett JMS, Sgroi DC, Treuner K, et al. Breast cancer index is a predictive biomarker of treatment benefit and outcome from extended tamoxifen therapy: final analysis of the trans-attom study [J]. Clin Cancer Res, 2022, 28(9): 1871-1880.
[29]
Noordhoek I, Treuner K, Putter H, et al. Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HR(+) early-stage breast cancer for 10 years of endocrine therapy [J].Clin Cancer Res, 2021, 27(1): 311-319.
[30]
Filipits M, Dubsky P, Rudas M, et al. Prediction of distant recurrence using EndoPredict among women with ER(+),HER2(-) node-positive and node-negative breast cancer treated with endocrine therapy only[J]. Clin Cancer Res, 2019, 25(13): 3865-3872.
[31]
Mamounas EP, Liu Q, Paik S, et al. 21-gene recurrence score and locoregional recurrence in node-positive/ER-positive breast cancer treated with chemo-endocrine therapy [J]. J Natl Cancer Inst, 2017,109(4):djw259.
[32]
Bilani N, Crowley F, Mohanna M, et al. Does the 21-gene recurrence score have clinical utility in HR+/HER2+breast cancer? [J]. Breast,2022,66:49-53.
[33]
Llombart-Cussac A, Pérez-García J, Brasó-Maristany F, et al.HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: a correlative analysis from the PHERGain phase Ⅱtrial [J]. Clin Cancer Res, 2024, 30(18):4123-4130.
[34]
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J]. Lancet, 2014, 384(9938): 164-172.
[35]
Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial [J]. JAMA Oncol, 2020, 6(5):676-684.
[36]
Lehmann BD, Jovanovi c' B, Chen X, et al. Refinement of triplenegative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection [J]. PLoS One, 2016, 11(6): e0157368.
[37]
Asleh K, Lluch A, Goytain A, et al. Triple-negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine [J]. Clin Cancer Res, 2023, 29(2): 389-400.
[38]
Jimenez MM, Gluz O, Villacampa G, et al. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy [J]. Ann Oncol,2024,35:S312.
[1] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[2] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[3] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[4] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[5] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[6] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[7] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[8] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[9] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[10] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[13] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[14] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[15] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
阅读次数
全文


摘要